Antengene (6996) Jefferies Global Healthcare Conference 2025 Presentation summary

Pipeline highlights and clinical progress

• ATG-022 (CLDN18.2 ADC) achieved 40% ORR and 90% DCR in moderate-to-high CLDN18.2 expressing gastric cancer, and 30% ORR and 50% DCR in low/ultra-low expressors, with durable responses over 21 months in some patients.

• ATG-022 demonstrated efficacy across all CLDN18.2 expression levels and a favorable safety profile, with no ophthalmological or interstitial lung disease observed.

• ATG-037 (CD73 inhibitor) showed 36.4% ORR in CPI-resistant melanoma and 22.2% ORR in CPI-resistant NSCLC in combination with pembrolizumab, with strong preclinical and clinical activity.

• The AnTenGager™ TCE 2.0 platform enables safer, more effective T cell engagers for solid tumors, hematological malignancies, and autoimmune diseases, with multiple assets advancing toward IND.

• ATG-201 (CD19 x CD3 TCE) demonstrated deep and durable B cell depletion with reduced cytokine release, targeting autoimmune diseases with IND expected in H2 2025.

Market opportunity and strategic positioning

• Claudin 18.2 positive gastric cancer represents a large, underpenetrated global market, with over 1.4 million addressable patients and a $10B+ market size in the US alone.

• Immuno-oncology market for solid tumors is projected to exceed $140B by 2028, with significant unmet needs in IO-resistant cancers.

• ATG-037 targets a substantial population of melanoma patients progressing on anti-PD-1 therapy, with over 70,000 advanced melanoma patients globally.

• The AnTenGager™ platform is designed for broad applicability, aiming to transform treatment in solid tumors, hematological malignancies, and autoimmune diseases.

• Cash and bank balances of $125M provide a three-year runway to advance pipeline development and strategic initiatives.

Differentiation and innovation

• ATG-022 is differentiated by its ability to target all CLDN18.2 expression levels, outperforming competitors and maximizing commercial potential.

• ATG-037 exhibits superior CD73 inhibition compared to AB680, with higher activity in human plasma and potent reversal of T cell inhibition.

• The AnTenGager™ TCE 2.0 platform uses steric hindrance masking and proprietary anti-CD3 sequences to minimize cytokine release and improve safety.

• ATG-201's bivalent binding enables effective depletion of low-expressing CD19+ B cells, addressing the unique biology of autoimmune diseases.

• In-house developed drugs are entering pivotal trials, supporting a multi-market revenue ramp-up and readiness for business development.